This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conjugate Veterinary Vaccine Development
Conjugate veterinary vaccines are developed when the primary antigen lacks adequate immunogenicity. In such scenarios, the weaker antigen is chemically coupled to a more potent one, amplifying the immune response to the less immunogenic component. A frequent example involves linking polysaccharides to robust antigens. BioVenic provides these specialized services to support clients in crafting conjugate veterinary vaccines tailored to combat infections induced by particular pathogens. By availing these services, we accelerate your veterinary vaccine development process, thereby helping fortify animals' immune defenses and preserve animal health.
Veterinary Conjugate Vaccine Development Solution
BioVenic offers relevant services to assist your veterinary vaccine development. The following diagram shows the process of conjugate vaccine development.
| Preparation of Polysaccharide Antigen | It is prepared by bacterial culture and extraction, or chemical synthesis. |
| Glycoconjugate Preparation | Antigens are binding products of polysaccharide antigens to protein carriers and are prepared by methods such as chemical or biosynthesis. |
| Vaccine Formulation Development | Components such as immunogens and adjuvants are mixed into a vaccine formulation. |
| Immunogenicity Assessment | Vaccine samples are injected into animals to stimulate an immune response and cause them to develop immunity. The immunizing effect of the vaccine is assessed by detecting antibody levels in serum samples. |
Fig.1 Conjugate vaccine development process.1
Our Services
Polysaccharide Conjugate Synthesis
Polysaccharide conjugates in vaccines on the market are mostly chemically prepared. In recent years, biocoupling technology has gradually emerged, which has certain advantages in the preparation and upgrading optimization of polysaccharide conjugate vaccines. Both technology platforms are available in BioVenic to meet your conjugate veterinary vaccine research and development requirements.
| Synthesis Platforms | ||
| Description | Direct coupling of bacterial polysaccharides and proteins by chemical cross-linking. | After the induced expression of the engineered bacterial strain, the heterologous target polysaccharide was transferred to the carrier protein catalyzed by glycosyltransferase, and the glycoprotein was finally purified. |
| Advantages |
|
|
| Limitations |
|
|
Formation Development
Carbohydrate antigens are covalently linked to carrier proteins, which, unlike natural carbohydrates, induce a T-cell-dependent immune response. Addition of immunostimulants, adjuvants, helps to boost the immune system to provide a strong response. BioVenic provides formulation development services for conjugate veterinary vaccines, evaluating and comparing the changes in vaccine safety and immunogenicity with the addition of different adjuvants, excipients and other components to provide you with the most competitive vaccine formulations, and stability assessment services to examine the changes in the effectiveness of the finished vaccine under transportation and storage conditions.
Immunogenicity Assessment
Immunogenicity assessment is a crucial part of the veterinary conjugate vaccine development process, and is used to determine whether the vaccine is capable of stimulating an adequate immune response. BioVenic selects the appropriate animal model for you, determines the vaccine dose for each animal in the immunization experiment, and develops a detailed immunization protocol, including the immunization dose, vaccination time point and immunization route, to ensure that the immunization protocol can induce an immune response within a certain period. Meanwhile, blood samples are collected periodically after immunization to assess the antibody level and neutralization ability by ELISA and other immunological methods. For cellular immune response assessment, the company provides a flow cytometry platform to detect T-cell activation and cytokine production.
Quality Control
Considering the process of conjugate veterinary vaccine development, strict quality control is required to maintain the safety, stability and efficacy of the final product.
Raw Materials
We maintain strict quality control of all raw materials used in vaccine preparation, including antigens, adjuvants, carrier proteins, polysaccharide antigens, etc. We ensure that the source of raw materials and the process of their preparation meet quality standards and are validated.
Production Process
Production process control programs are developed and implemented to ensure consistent vaccine quality and to monitor and record key parameters of the production process, such as temperature, pH, concentration.
Component Analysis
BioVenic uses highly efficient analytical methods, such as high performance liquid chromatography mass spectrometry (HPLC-MS), to verify the purity and consistency of conjugate veterinary vaccine components.
Why Choose Us?
BioVenic has deep experience in polysaccharide preparation and optimization, including extraction and purification of polysaccharide antigens from target pathogens.
BioVenic is well versed in a variety of carrier coupling technologies, whether chemically or biosynthesized, to covalently link polysaccharide antigens to appropriate carrier proteins or molecules.
BioVenic's stringent quality control system ensures consistency and stability throughout the preparation process.
These strengths enable us to provide high-quality, efficient, and highly customized services in the conjugate veterinary vaccine development process. BioVenic understands the importance of each development step and ensures the quality and immunogenicity of the final product with our expertise and quality control. Please don't hesitate to contact us to accelerate your vaccine development and meet the ever-changing challenges of animal health.
Reference
- Seeberger, Peter H. "Discovery of semi-and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach: focus review." Chemical Reviews 121.7 (2021): 3598-3626.